INTRODUCTION
============

ATP-binding cassette transporter A1 (ABCA1) mediates the transport of cholesterol and phospholipids from cells to lipid-poor apolipoproteins. Animal and human studies have documented that defects in the ABCA1 pathway are determinants of coronary heart disease (CHD) \[[@R1]\].Inactivation of *ABCA1* gene in macrophages increases atherosclerotic lesions in hyperlipidemic mice \[[@R2]\] and overexpressing human ABCA1 in transgenic mice retards atherogenesis \[[@R3]\]. Several *ABCA1* gene polymorphisms have been identified, such as *rs2230806* (*R219K*) in the chromosomal position 107620867, *rs2230808* (*R1587K*) in the chromosomal position 106602625 and *rs4149313* (*I883M*) in the chromosomal position 106626574. Clee *et al* \[[@R4]\] genotyped 804 Dutch men with CHD who participated in the Regression Growth Evaluation Statin Study (REGRESS) and found that *K* allele carriers had decreased progression of atherosclerosis and a reduced risk of coronary events.

The aim of the study, in line with our previous work \[[@R5]-[@R7]\], was to evaluate the *R219K*, *R1587K* and *I883M* of *ABCA1* gene polymorphisms according to lipid profile.

MATERIALS AND METHODOLOGY
=========================

Subjects
--------

The genotyping of 447 Greek nurses (81% women) aged \[median (range)\] 22.5 (18.0-57.0) years that attended the University of Nursing of Technological and Educational Institution was performed. All subjects were self-reported as being healthy. The exclusion criteria were: any known chronic disease such as cardiovascular disease, diabetes mellitus, hypertension, hypothyroidism and renal or liver disease. Also, the subjects with professional exercise performance were excluded.

SUBJECT SUBGROUPS
-----------------

### According to Lipid Profile

All subjects were divided to 2 groups according to lipid profile \[total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), triglycerides (TG) and apolipoprotein (apo) A.\]

We applied the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Adult Treatment Panel III (NCEP ATP III) classification of TC, LDL-C, HDL-C and TG \[[@R8]\]. Optimal lipid profile was defined as TC \<2 20 mg/dl, TG \<150 mg/dl, HDL-C \>40 mg/dl or LDL-C\<160 mg/dl. Non-Optimal lipid profile was defined as TC \>220 mg/dl, TG \>150 mg/dl, HDL-C\<40 mg/dl or LDL-C \>160 mg/dl.

### According to Genotypes

We evaluated single nucleotide polymorphisms (SNPs) in chromosome 9 such as *rs2230806 (R219K)*in the position 107620867*, rs2230808 (R1587K)* in the position 106602625 and *rs4149313 (I883M*) in the position 106626574 according to lipid profile by using polymerase chain reaction (PCR) and restricted fragment length polymorphism analysis (RFLP's) (see below).

The University of Nursing of Technological and Educational Institution ethics committee approved the study. All subjects signed an informed consent form.

### DNA Analysis and Determination of Blood Lipids

The *ABCA1* gene polymorphisms (*R219K, R1587K* and *I883M*) were detected using PCR and RFLP's. The PCR was performed using Taq polymerase KAPATaq.

For *R219K* polymorphism the oligonucleotide primers which were used were AAAGACTTCAAGGACCCA**G**CTT and CCTCACATTCCGAAAGCATTA \[[@R9]\]. PCR was subjected to 95^ο^C for 5 min, 30 cycles of 95^ο^C for 30 s, 55^ο^C for 30 s and 72^ο^C for 30 s and final extension to 72^ο^C for 7 min, producing a fragment of 309 bp. This fragment was subsequently cleaved by EcoNI, creating fragments for R allele 309 bp and for K allele 184 bp and 125 bp, which were subjected to electrophoresis on an agarose gel 3% and visualized with ethidium bromide.

For *R1587K* polymorphism the oligonucleotide primers which were used were AAGATTTATGACAGGACTG GACAC**G**A and TGAATGCCCCTGCCAACTTTAC \[[@R10]\]. PCR was subjected to 95^ο^C for 5 min, 30 cycles of 95^ο^C for 30 s, 60^ο^C for 30 s and 72^ο^C for 30 s and final extension to 72^ο^C for 7 min, producing a fragment of 139 bp. This fragment was subsequently cleaved by BssSI, creating fragments for R allele 117 bp and 22 bp and for K allele 139 bp, which were subjected to electrophoresis on an agarose gel 3% and visualized with ethidium bromide.

The oligonucleotide primers used for *I883M* polymor-phism were 5'-GAGAAGAGCCACCCTGGTTCCAACCA GAAGAGGAT-3' and 5'- AGAAAGGCAGGAGACAT CGCTT −3 as described by Clee SM *et al* \[[@R4]\]. PCR was subjected to 95^ο^C for 5 min, 30 cycles of 95^ο^C for 30 s, 65^ο^C for 30 s and 72^ο^C for 30 s and final extension to 72^ο^C for 7 min, producing a fragment of 132 bp. This fragment was subsequently cleaved by EcorV, creating fragments for I allele 97 bp and 35 bp and for M allele 132 bp, which were subjected to electrophoresis on an agarose gel 4% and visualized with ethidium bromide.

### Statistical Analysis

All data except for total and LDL-C deviated from normality (Kolmogorov-Smirnov test). Non-normally distributed continuous variables are shown as median and interquartile range (25^th^, 75^th^ percentile), while total cholesterol and LDL-C concentrations are presented as mean ± SD (Standard Deviation). All categorical variables are presented as relative (percentage) frequencies. The Kruskal-Wallis H statistic or One Way ANOVA, where appropriate, were used to compare continuous variables among the 3 genotype groups, while the Mann-Whitney U test or the Student's t-Test, where appropriate, were used to compare the continuous variables between the 2 groups of carriers. All tests were 2-sided at a significance level of p \<0.05. Data were analyzed using SPSS™ (Version 11.5, Chicago IL, USA).

RESULTS
=======

Clinical and Laboratory Parameters
----------------------------------

Clinical characteristics and laboratory parameters of the study groups are shown in Table **[1](#T1){ref-type="table"}** and Table **[2](#T2){ref-type="table"}**.

The polymorphisms frequency are shown in Table **[3](#T3){ref-type="table"}** and Table **[4](#T4){ref-type="table"}**.

There was no difference in *R219K*, *R1587K* and *I883M*polymorphisms frequency according to Optimal and Non-Optimal lipid profile (p = 0.49, 0.29 and 0.42, respectively).

### Logistic Regression

Subjects with *RK*(*R1587K* polymorphism) had 68.8% increased risk on average of having LDL-C above normal limits as compared with those with *RR* genotype \[Odds Ratio (OR): 1.688, p = 0.010, 95% Confidence Intervals (CI) 1.131-2.520.\] Similarly subjects with *K* allele (*R1587K* polymorphism) had 59% increased risk on average of having LDL-C above normal limits as compared with those with *R* allele (OR: 1,590, p = 0.016, 95% CI 1.090-2.319).

DISCUSSION
==========

We examined the impact of the *R219K*, *R1587K* and *I883M* of *ABCA1* polymorphisms as a genetic influence on the lipid profile in Greek subjects. In this context, the possible effects of the *ABCA1* polymorphisms on lipids or cardiovascular disease were recently evaluated in various populations such as Japanese \[[@R11]\] in which correlation with HDL-C concentrations was found, Saudi \[[@R12]\] in which the *ABCA1 C69T* gene frequency was higher in healthy subjects compared with diabetic patients, Chinese \[[@R13]\], in which *ABCA1* gene *R219K* polymorphism was associated with ischemic stroke, Greek \[[@R5]-[@R7]\] in which a gender-specific effect of the *R219K* polymorphism on plasma lipids was demonstrated, Turkish \[[@R14]\] in which a gender-specific effect of the *R219K* polymorphism on plasma lipids and CHD was shown and Mexican \[[@R15]\] in which several European loci as well as a novel one for high TG and low HDL-C levels were identified. However, the results are still confusing.

Similarly, the possible influence of *ABCA1* gene polymorphisms on Alzheimer disease was previously evaluated. The relationship between *ABCA1 R219K, R1587K* and *I883M* and Alzheimer disease has been reported in various ethnic groups with contradictory results. A meta-analysis of 13 studies involving 12,248 subjects did not support the opinion that *ABCA1* is a major genetic risk factor for Alzheimer disease \[[@R16]\].

With regard to subgroups with low HDL-C, Hodoğlugil *et al.* \[[@R17]\] reported that *R219K* and *I883M* polymorphisms were related to higher HDL-C levels, Slatter *et al.* \[[@R18]\] found that *R1587K* was overexpressed in low HDL-C individuals, whereas Frikke-Schmidt *et al.* \[[@R19]\] did not observe any association with *R219K* but reported that *R1587K*polymorphism was overexpressed in individuals with low HDL-C concentrations. In subgroups with high HDL-C, Kakko *et al.* \[[@R20]\] found a minor association between *ABCA1* polymorphisms and HDL-C levels in women, whereas Clee *et al.* \[[@R4]\] reported a non-significant trend towards higher HDL-C levels in carriers of *R219K*. As for TG concentrations, there is also inconsistency between research groups. For example, Clee *et al.* \[[@R4]\] reported that carriers of *K* allele of *R219K* polymorphism had significantly lower TG levels in relation to carriers of the *R* allele, whereas others did not find any associations. Coban *et al.* \[[@R14]\] demonstrated the interaction of TG elevation (\>140 mg/dL) with CHD in female *219RK* genotype carriers. Delgado-Lista *et al.* \[[@R21]\] reported a trend for lower fasting TG and large TG-rich lipoproteins in minor allele carriers compared with major allele homozygotes of R219K polymorphism. In our study with young Greek nurses (living and working in similar conditions) we did not observe any association of *R219K* polymorphism with HDL-C or other lipid levels, although we found that individuals with *RK* genotype of *R1587K* polymorphism had significantly higher TC, LDL-C and TG levels compared with the *RR* genotype \[[@R7]\]. These discrepancies may be attributed to environmental factors such as diet, smoking and physical activities. Sandhofer *et al.* \[[@R22]\] found that *K* allele of *R219K* gene displayed a lower intima media thickness and a reduced risk of advanced plaque extent compared with non-carriers only in non-smokers and concluded that smoking abrogates the protective effect of the *R219K*. Cenarro *et al.* \[[@R23]\] reported that the *K* allele of the *R219K*gene was significantly more frequent in familial hypercholesterolemia subjects without premature CHD than in familial hypercholesterolemia subjects with premature CHD and it appears to be more protective for smokers than non-smokers.

The *R1587K* polymorphism is located in one of the two extracellular loops of the ABCA1 protein. This location is important for the interaction of apo A1 and for the efflux of cholesterol \[[@R19]\]. In our study, no association between *R1587K* polymorphism and HDL-C levels was found.

In conclusion, the *R1587K* polymorphism of *ABCA1 g*ene was associated with altered lipid levels in young Greek nurses. Further research in larger populations is needed to establish such associations and determine their clinical implications.
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###### 

Demographic data.

  **Variable**            **Median (Range)**
  ----------------------- --------------------
  Age (years)             22.5 (57.0-18.0)
  Height (cm)             166 (207-150)
  Weight (Kg)             62 (132-40)
  BMI (m/Kg^2^)           22.3 (44.0-16.0)
  Waist (cm)              88 (143-48)
  SBP (mmHg)              110 (145-80)
  DBP (mmHg)              70 (90-40)
                          N (%)
  Gender                  
  Male                    87 (19.4)
  Female                  361 (80.6)
  Smoking                 
  Yes                     175 (39.1)
  No                      246 (54.9)
  Ex-smokers              26 (6)
  Family History of CHD   
  Yes                     92 (20.5)
  No                      296 (66.1)
  Not Known               59 (13.4)

BMI = Body mass index, SBP = Systolic blood pressure, DBP = Diastolic blood pressure, CHD = Coronary heart disease

###### 

Study group lipid profile.

  **Variable**                **Mean ± SD/Median (Range)**
  --------------------------- ------------------------------
  Total Cholesterol (mg/dl)   202 ± 66
  LDL cholesterol (mg/dl)     107 ± 46
  HDL cholesterol (mg/dl)     65 (140-16)
  Triglycerides (mg/dl)       97 (523-12)
  Apolipoprotein A (mg/dl)    147 (200-100)

LDL = Low density lipoprotein, HDL = High density lipoprotein

###### 

Genotype and allele frequencies in the whole cohort.

  **R219K**   **R1587K**   **I883M**                     
  ----------- ------------ ----------- ------------ ---- ------------
  RR          225 (50.2)   RR          211 (47.1)   II   309 (69.0)
  RK          191 (42.6)   RK          193 (43.1)   IM   131 (29.2)
  KK          32 (7.1)     KK          44 (9.8)     MM   8 (1.8)
  R           71.5         R           68.6         I    83.6
  K           28.5         K           31.4         M    16.4

###### 

Lipid profile according to 3 ABCA1 gene polymorphisms.

  ** **      ** **     **TC (mg/dl) Mean ± SD**   **TGs (mg/dl) Median (IQR)**   **HDL cholesterol (mg/dl) Median (IQR)**   **LDL cholesterol (mg/dl) Mean ± SD**   **Apo A1 (mg/l) Median (IQR)**
  ---------- --------- -------------------------- ------------------------------ ------------------------------------------ --------------------------------------- --------------------------------
   *R219K*   RR        200±64                     98 (523-12)                    66 (200-25)                                106±45                                  1.49 (3.0-1.0)
  RK         203±67    98 (481-18)                64 (191-16)                    106±45                                     1.53 (3.0-1.0)                          
  KK         213±68    95 (306-37)                63 (126 -41)                   122 ±47                                    1.64 (3.0-1.0)                          
             P value   0.561                      0.708                          0.923                                      0.169                                   0.100
  *R1587K*   RR        197±67                     95 (481-12)                    65 (200-24)                                100±45                                  1.45 (3.0-1.0)
  RK         209±61    103 (441-12)               65 (156-16)                    114±43                                     1.48 (3.0-1.0)                          
  KK         200±76    85 (523-25)                62 (155-30)                    108±53                                     1.43 (3.0-1.0)                          
             P value   0.185                      0.395                          0.735                                      0.011                                   0.848
  *I883M*    II        200±67                     99 (523-12)                    65 (200-16)                                105±47                                  1.4 (3.0-1.0)
  IM         205±62    91 (472-30)                65 (155-33)                    100±42                                     1.5 (3.0-1.0)                           
  MM         211±63    170 (321-42)               68 (122-41)                    103±38                                     1.5 (2.0-1.0)                           
             P value   0.740                      0.486                          0.818                                      0.633                                   0.574

TC = total cholesterol, LDL = Low density lipoprotein, HDL = High density lipoprotein, TG = triglycerides
